The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials

nork Marchetti, S, Schellens, J H M
Argitaratua 2007

Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.

nork Schellens, J H, van der Wart, J H, Breimer, D D
Argitaratua 1990

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

nork Gerrits, C. J., de Jonge, M. J., Schellens, J. H., Stoter, G., Verweij, J.
Argitaratua 1997

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen

nork Jager, N. G. L., Rosing, H., Linn, S. C., Schellens, J. H. M., Beijnen, J. H.
Argitaratua 2012

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

nork Ma, J., Verweij, J., Kolker, H. J., van Ingen, H. E., Stoter, G., Schellens, J. H.
Argitaratua 1994

Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man.

nork Schellens, J H, Soons, P A, van der Wart, J H, Hoevers, J W, Breimer, D D
Argitaratua 1991

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer

nork Kordes, S., Klümpen, H. J., Weterman, M. J., Schellens, J. H. M., Richel, D. J., Wilmink, J. W.
Argitaratua izan da Cancer Chemother Pharmacol (2015)

Essential medicines for breast cancer in low and middle income countries

nork Bazargani, Y. T., de Boer, A., Schellens, J. H. M., Leufkens, H. G. M., Mantel-Teeuwisse, Aukje K.
Argitaratua izan da BMC Cancer (2015)

Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.

nork Schellens, J H, van der Wart, J H, Danhof, M, van der Velde, E A, Breimer, D D
Argitaratua 1988

Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.

nork de Wit, R., Beijnen, J. H., van Tellingen, O., Schellens, J. H., de Boer-Dennert, M., Verweij, J.
Argitaratua 1996

PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line

nork Harmsen, Stefan, Meijerman, I., Febus, C. L., Maas-Bakker, R. F., Beijnen, J. H., Schellens, J. H. M.
Argitaratua 2009

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice

nork Oostendorp, Roos L., Buckle, T., Lambert, G., Garrigue, J. S., Beijnen, J. H., Schellens, J. H. M., van Tellingen, O.
Argitaratua 2010

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

nork Ma, J., Maliepaard, M., Nooter, K., Loos, W. J., Kolker, H. J., Verweij, J., Stoter, G., Schellens, J. H.
Argitaratua 1998

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

nork Tellingen, O van, Huizing, M T, Panday, V R Nannan, Schellens, J H M, Nooijen, W J, Beijnen, J H
Argitaratua 1999

Evaluation of α(2)-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies

nork Keizer, Ron J., Funahashi, Y., Semba, T., Wanders, J., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R.
Argitaratua 2011

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option

nork Meulendijks, D, Dewit, L, Tomasoa, N B, van Tinteren, H, Beijnen, J H, Schellens, J H M, Cats, A
Argitaratua izan da Br J Cancer (2014)

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

nork Verheijen, R. B., Swart, L. E., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R., Steeghs, N.
Argitaratua izan da Cancer Chemother Pharmacol (2017)

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

nork Verheijen, R. B., Swart, E. L., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R., Steeghs, N.
Argitaratua izan da Cancer Chemother Pharmacol (2020)

Bioanalysis of the novel peptide anticancer drug kahalalide F in human plasma by h.p.l.c. under basic conditions coupled with positive turbo-ionspray tandem mass spectrometry

nork Stokvis, E, Rosing, H, López-Lázaro, L, Jimeno, J M, Supko, J G, Schellens, J H M, Beijnen, J H
Argitaratua 2002

Randomized phase I and pharmacological study of weekly or 2-weekly gemcitabine and cisplatin in advanced non-small cell lung cancer

nork Crul, M, Schoemaker, N, Baas, P, Pluim, D, Sparidans, R, Beijnen, J H, Van Zandwijk, N, Schellens, J H M
Argitaratua 2002